MED8

Across TCGA pan-cancer cohorts, MED8 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of MED8’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where MED8 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types MED8 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

HNSC, LUAD, and CCRCC are the cancer types where MED8 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MED8 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	All	+0.377	<.001	11	view →
LUAD	Male	All	+0.462	<.001	9	view →
CCRCC	Male	All	+0.204	<.001	9	view →
LSCC	Male	All	+0.623	<.001	8	view →
COAD	Female	III,IV	+0.331	<.001	8	view →
OV	All	All	+0.527	.002	2	view →
PDAC	All	IV	−0.383	.044	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

MED8–HNSC

Open the HNSC breakdown →